| 摘要 |
Novel carboxyalkyldipeptides, their preparation and pharmaceutical compositions containing them. The novel dipeptides are represented by general formula (I), where A is selected from formula (II), with n, p and q being specified values from 0 to 2, B is -[J]-[L]-[M]-; D is formula (III), E is -NH-, -O-, -S-, or -CH2-; G is formula (IV) or -SO2-; J is -(CH2)s- or -((CH2)t-W-; where L is chemical bond, specified alkyl, aryl or heterocyclic moieties, M is -(CH2)u- or -((CH2)t-X-(CH2)v)- where n and v are 0-5 and X is -NR<9>-, -O-, -S-, formula (V) or formula (VI), R<1> and R<2> are hydrogen, lower alkyl or lower acyl; R<3> is hydrogen, lower alkyl, haloloweralkyl, phenylloweralkyl, (cycloalkyl)lower alkyl, aminomethyl, lower alkylaminomethyl, phenylloweralkylaminomethyl, (cycloalkyl)loweralkylaminomethyl, loweralkylthiomethyl, haloloweralkylthiomethyl, 2-, 3- or 4-pyridylloweralkyl, 2-, 4- or 5-thiazolylloweralkyl, 2-, 4- or 5-1H-imidazolylloweralkyl, 1-imidazolylloweralkyl, 1-morpholinoloweralkyl or hydroxyphenylloweralkyl; R<4> is chlorine or CF3; R<5> is hydrogen, halogen, lower alkyl, lower acyl, lower alkoxy, haloloweralkyl or phenylloweralkyl; R<7> is hydrogen, lower alkyl or aminoloweralkyl; R<6> and R<8> are hydroxy or specified substituted hydroxy groups. The compounds exhibit angiotensin converting enzyme inhibitory activity and/or diuretic activity. |
